Financial results - SONOMED BIOLIFE S.R.L.

Financial Summary - Sonomed Biolife S.r.l.
Unique identification code: 36723890
Registration number: J03/1860/2016
Nace: 8622
Sales - Ron
110.371
Net Profit - Ron
50.853
Employee
The most important financial indicators for the company Sonomed Biolife S.r.l. - Unique Identification Number 36723890: sales in 2023 was 110.371 euro, registering a net profit of 50.853 euro and having an average number of employees. Firma isi desfasoara activitatea in domeniul Activitati de asistenta medicala specializata having the NACE code 8622.

Sales, Profit, Employees, Debts, Capitals, Financial Results - Sonomed Biolife S.r.l.

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sales - EUR - - 1.211 32.914 43.857 54.605 68.108 97.367 116.686 110.371
Total Income - EUR - - 1.211 35.478 43.859 54.629 68.129 99.152 120.230 114.542
Total Expenses - EUR - - 1.067 21.819 26.573 27.792 31.443 35.398 54.916 62.584
Gross Profit/Loss - EUR - - 144 13.660 17.286 26.838 36.686 63.755 65.314 51.958
Net Profit/Loss - EUR - - 132 13.308 16.848 26.292 36.069 62.781 64.145 50.853
Employees - - 1 2 2 2 2 4 4 0
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded. In the last year of activity, the sales decreased by -5.1%, from 116.686 euro in the year 2022, to 110.371 euro in 2023. The Net Profit decreased by -13.098 euro, from 64.145 euro in 2022, to 50.853 in the last year.

Check the financial reports for the company - Sonomed Biolife S.r.l.

Rating financiar

Financial Rating -
Sonomed Biolife S.r.l.

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Check Financial Rating
Limite de plata

Payment Limits -
Sonomed Biolife S.r.l.

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Sonomed Biolife S.r.l.

It determines the risk of insolvency based on the submitted accounting balance.

Check Insolvency Probability
Rapoarte financiare

Financial Reports -
Sonomed Biolife S.r.l.

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Sonomed Biolife S.r.l. - CUI 36723890

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fixed Assets - - 29 8.813 8.322 7.560 7.495 23.533 19.256 66.434
Current Assets - - 1.767 35.497 68.645 93.092 116.976 131.785 119.289 163.968
Inventories - - 525 0 0 0 0 0 0 0
Receivables - - 589 27.776 67.073 89.663 113.979 111.709 111.964 161.582
Cash - - 652 7.721 1.573 3.429 2.997 20.076 7.325 2.386
Shareholders Funds - - 177 13.482 30.082 55.791 90.803 90.925 94.519 145.085
Social Capital - - 45 44 43 42 41 40 41 40
Debts - - 2.062 30.828 46.885 44.862 33.669 55.475 38.485 71.663
Income in Advance - - 0 0 0 0 0 8.918 5.542 13.654
Exchange rate - RON 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445 4.4821
Main CAEN "8622 - 8622"
CAEN Financial Year 8622
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 163.968 euro in 2023 which includes Inventories of 0 euro, Receivables of 161.582 euro and cash availability of 2.386 euro.
The company's Equity was valued at 145.085 euro, while total Liabilities amounted to 71.663 euro. Equity increased by 50.853 euro, from 94.519 euro in 2022, to 145.085 in 2023. The Debt Ratio was 31.1% in the year 2023.

Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.

Subscriptions Financial Reports

You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.

Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!

Reviews - Sonomed Biolife S.r.l.

Comments - Sonomed Biolife S.r.l.

Similar services useful for checking companies and business development.

Contacts Firms

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Company Lists

Create lists of companies for your sales activity according to your own criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.